Sajjad Saeed, MD
Infectious Disease · East China, MINPI 1972573681
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Gilead at 25.2% of the total.
Across 155 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$837
- Viiv Healthcare Company$664
- Merck$486
- Takeda Pharmaceuticals U.S.A., Inc.$383
- Insmed, Inc.$326
- Smith+Nephew$90
- plus $542 from 14 others
What the payments were for
- Food & beverage$3,19896%
- Education$1304%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 48 | $837 |
| Viiv Healthcare Company | 27 | $664 |
| Merck | 23 | $486 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $383 |
| Insmed, Inc. | 15 | $326 |
| Smith+Nephew | 4 | $90 |
| Janssen Products, LP | 1 | $80 |
| AbbVie | 3 | $79 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $78 |
| Johnson & Johnson(2 entities) | 2 | $48 |
| Novartis | 2 | $45 |
| CSL Behring | 2 | $36 |
| Paratek Pharmaceuticals, Inc. | 2 | $35 |
| Ferring Pharmaceuticals Inc. | 2 | $30 |
| Argenx US, Inc. | 1 | $25 |
| Cashflow Solutions, LLC | 1 | $22 |
| Solventum Corporation | 1 | $20 |
| Lilly USA, LLC | 1 | $16 |
| Melinta Therapeutics, LLC | 1 | $14 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CABENUVA$125
How this compares
$3,328 in reported general payments places this provider in the 85th percentile of 257 infectious disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 128 | $499,444 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 41 | $176,154 |
| DescovyEmtricitabine/Tenofov Alafenam | 28 | $60,558 |
| JulucaDolutegravir/Rilpivirine | 16 | $54,300 |
| StribildElviteg/Cob/Emtri/Tenofo Disop | 12 | $44,322 |
| TivicayDolutegravir Sodium | 17 | $35,882 |
| ErtapenemErtapenem Sodium | 33 | $24,747 |
| IsentressRaltegravir Potassium | 11 | $22,451 |
| Daptomycin | 51 | $17,476 |
| XareltoRivaroxaban | 16 | $12,744 |
| Vancomycin Hcl | 86 | $12,356 |
| Testosterone | 13 | $6,076 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 43 | $4,811 |
| Cefepime Hcl | 28 | $4,235 |
| Meropenem | 21 | $3,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy, Stribild | $837 | $780,478209 claims |
| Viiv Healthcare CompanyJuluca, Tivicay | $664 | $90,18233 claims |
| MerckIsentress | $486 | $22,45111 claims |
| Johnson & JohnsonXarelto | $48 | $12,74416 claims |
| AbbVieSynthroid | $79 | $60813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 257 infectious disease providers in Michigan.
Other infectious disease in East China
- Peter GulickLansing$850K
- Teena ChopraDetroit$328K
- Indira BrarDetroit$323K
- Keith KayeAnn Arbor$187K
- Rodger MacarthurDetroit$150K
- Chris FarnumLansing$102K
- Pranatharthi ChandrasekarDetroit$71K
- Mayur RameshDetroit$30K
- Christopher CarpenterRoyal Oak$27K
- Marcus ZervosDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.